32 results about "Dermatitis repens" patented technology

The application provides a drying method of Chuanxiong medicinal material and application of Chuanxiong or its extract in preparation of an external medicine for treating atopic dermatitis. The drying method of Chuanxiong medicinal material improves Chuanxiong processing efficiency, shortens processing period, obtains by-product Chuanxiong extract in addition to preparation of decoction pieces, reduces energy consumption and lowers production cost. The Chuanxiong essential oil and Chuanxiong extract are both composed of small molecule components, have good affinity to skin, are absorbed through skin quickly, can quickly relieve symptoms such as itching and skin damage caused by atopic dermatitis, and are natural, safe and free of side effects. Meanwhile, the small molecule components contained in the Chuanxiong essential oil and Chuanxiong extract have good lipophilicity, have softening effect on the thickened stratum corneum caused by atopic dermatitis, and are more conducive to drug absorption. In addition, the Chuanxiong essential oil and Chuanxiong extract are simple to prepare and low in price.

The application discloses application of a human lactoferricin peptide in anti-inflammatory soothing and skin barrier repair. The application relates to the field of biotechnology, and provides application of a polypeptide or a biological material related to the polypeptide in preparation of a product with anti-inflammatory soothing and / or skin barrier repair functions; the polypeptide is a human lactoferricin peptide derived from a filtrate of a yeast fermentation lysate product, and an amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide has intervention potential on inflammation related to dermatitis and eczema, especially on atopic dermatitis. The polypeptide can be applied to the fields of medicines and cosmetics.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

This invention discloses an essence for repairing hormone-induced facial dermatitis and its application, belonging to the field of cosmetics and skin repair technology. The essence uses deionized water as the main solvent, with butylene glycol and glycerin as the core moisturizing base. It is compounded with five major active ingredients: niacinamide, Bacillus ferment precipitate, mussel extract, sodium hyaluronate, and allantoin, supplemented with auxiliary components such as 1,3-propylene glycol, capryloyl hydroxamic acid, 1,2-hexanediol, ethylhexylglycerin, disodium EDTA, and ethanol. Through scientific compounding, a synergistic repair system is formed, achieving integrated effects of skin barrier repair, anti-inflammatory soothing, microecological balance regulation, deep moisturizing and water locking, and redness reduction and stabilization. The formula of this invention is gentle and non-irritating, free of hormones, fragrances, pigments, and strong allergens, suitable for use on hormone-induced facial dermatitis, dermatitis-prone skin, and severely sensitive skin. The product has good stability, high safety, and is suitable for industrial production, possessing significant skin repair value and promising market application prospects.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

This invention belongs to the field of biomedical nanomaterials and radiation damage drugs, specifically relating to a magnesium-ethylene glycol tetraacetic acid (EGTA) nanomedicine, its preparation method, and its applications. This study proposes using magnesium-EGTA nanomedicine to treat radiation dermatitis. EGTA's chelating ability for calcium ions is significantly higher than that of magnesium ions and other metal ions. Its unique ion selectivity provides an important theoretical basis and application potential for targeting and inhibiting mitochondrial calcium overload in the pathological process of radiation dermatitis. Magnesium ions are cofactors of many enzymes and have anti-inflammatory, collagen synthesis-promoting, and angiogenesis-enhancing effects. This study constructs a Mg-EGTA-based nanomedicine system, utilizing EGTA's stronger chelating ability for calcium ions, thereby achieving targeted regulation of mitochondrial calcium homeostasis through a calcium-magnesium ion intelligent replacement mechanism in response to calcium overload, providing new ideas and methods for the prevention and treatment of radiation dermatitis.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present invention discloses polypeptides and related substances against hair loss and dermatitis, and the uses thereof. Particularly, disclosed is the use of an osteocalcin-derived peptide, and homologous polypeptides, polypeptide-derived peptides or derivatives of the polypeptides and polypeptide-derived peptides, which use the osteocalcin-derived peptide as a skeleton and which are derived from different species, in preparing drugs for treating hair follicle recession and / or hair loss caused by psychological stress, seborrheic hair follicle recession and / or hair loss, acne and / or dermatitis caused by psychological stress and seborrheic acne and / or dermatitis. Further disclosed are the use, in preparing drugs, medical cosmetology products, cosmetics, health-care products, foods and additives for preventing and / or treating hair follicle recession, hair loss, acne and dermatitis, of substances capable of binding to a GPR158 receptor and modulating its activity.

The present application aims to provide a novel peptide which shows a rapid effect of drug efficacy and potency and has a long relief maintenance period, a medicament and an external agent containing the same, and particularly a preventive or therapeutic agent for dermatitis, rough skin, rhinitis, alopecia, thin hair, a hair growth agent, a hair growth promoting agent, an antipruritic agent, a skin care product, and the like. The present application achieves the above aim by providing an amino acid sequence represented by Formula I, a cyclic peptide or a derivative thereof having no peptide bond other than between the amino acids constituting the amino acid sequence, or a pharmaceutically acceptable salt thereof.

This invention provides an aromatic hydrocarbon receptor agonist with a benzofuran skeleton, its preparation method, and its application, belonging to the field of chemical synthetic drug technology. The compound has the structure shown in Formula I: Formula I. The small molecule compounds of this invention exhibit good agonistic activity against AHR in vitro and show good alleviating effects on psoriasis, inflammatory bowel disease, and atopic dermatitis. Some compounds show better anti-psoriasis effects than currently used clinical drugs.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

A set of antisense oligonucleotides specifically inhibiting thymic stromal lymphopoietin and the use thereof. The antisense oligonucleotide molecules have a length of 16-20 bases. The antisense oligonucleotide molecules have the following use: (1) in the preparation of a preparation for inhibiting the expression level of thymic stromal lymphopoietin; or (2) in the treatment of asthma, atopic dermatitis, chronic obstructive pulmonary disease, sinusitis, and nasal polyps.

A fire-retardant topical formulation comprising glycerol and urea in a ratio of 1:1 to 1:30 is provided. The formulation may further comprise polyvinyl pyrrolidone and / or ethylhexylglycerin, and / or a barrier forming agent and / or a stabilising agent. The formulation may be a moisturiser, shampoo, conditioner, hair dye, sun cream, aftersun composition, emollient or medical composition. The formulation may be for use in treating a skin condition, such as eczema, dermatitis, psoriasis, elderly dry and itchy skin, ichthyosis, rash, or infection. The composition when transferred to a fabric suppresses the flammability of the fabric and is also capable of being removed from the fabric by washing. A preferred formulation comprises 1% phenoxyethanol, 10% urea, 10% sodium lactate (60% solution), 1% lactic acid, 1% glycerol, 3% ethylhexylglycerin, 2% polyacrylate crosspolymer-6, 0.5% polyvinylpyrrolidone and 71.5% water by weight. A fire-retardant topical formulation comprising 1% glycerol, 2% polyacrylate crosspolymer-6, 10% sodium lactate solution, 1% phenoxyethanol, 1% lactic acid, 3% ethylhexylglycerin and 0.5% polyvinylpyrrolidone by weight is also disclosed. [Fig: None]

1. Name of the product in this design: Packaging Box (Jingbaitang Dermatitis King). 2. Purpose of this design: For packaging products. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention relates to a group of antisense oligonucleotides that specifically inhibit thymic stromal lymphopoietin and their applications. The antisense oligonucleotide molecules are 16-20 bases in length. This invention also relates to the following applications of the antisense oligonucleotide molecules (ASO): (1) preparing preparations that inhibit the expression of thymic stromal lymphopoietin; (2) treating asthma, atopic dermatitis, COPD, sinusitis and nasal polyps.

This invention belongs to the field of animal model construction technology, specifically providing a method for constructing and using a mouse radiation dermatitis model. The method involves irradiating localized areas of healthy mice with X-rays at a dose rate of 5.128 Gy / min in fractionated doses every other day, with a total dose of 30-49 Gy, to establish a mouse radiation dermatitis model. This invention uses a fractionated X-ray irradiation mode commonly used in clinical radiotherapy, which can stably induce radiation dermatitis of varying degrees. Skin damage is significantly dependent on the irradiation dose. A total dose of 30 Gy is optimal, and after 35 days of development, a standardized model closely resembling clinical grade II radiation dermatitis can be constructed. This method is simple to operate, has good reproducibility, and a low animal mortality rate. It can realistically simulate the skin damage process of clinical radiotherapy, providing a reliable basis for research on the mechanism of radiation dermatitis and is suitable for the screening and identification of related preventive and therapeutic drugs.

The present invention relates to a method for preparing a mixture of DNA fragments of high functionality derived from mushrooms, and a functional composition comprising the mixture of DNA fragments prepared by the method. Specifically, the present invention relates to a method for preparing a mixture of DNA fragments having uniform sizes within a prescribed range using specific restriction enzymes in mushrooms. According to the present invention, a functional composition having excellent effects of tissue interstitial support filling, skin condition improvement, tissue regeneration, wound healing, moisturizing, promotion of ECM synthesis, inhibition of cell aging, neovascularization, relief of inflammation, relief of pain, treatment of dermatitis such as atopic dermatitis, inhibition of hair loss, promotion of hair growth, and promotion of stem cell activity can be provided, using the mixture of DNA fragments as a main ingredient.

A composition for inhibiting sebum secretion is disclosed. The composition contains 3,4,5-trimethoxycinnamate thymol ester, a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient. The composition can inhibit sebum secretion in the skin or scalp, and further has useful effects such as the prevention or improvement of seborrheic dermatitis, seborrheic scalp dermatitis, or acne, or the tightening of pores. Methods for inhibiting sebum secretion employing 3,4,5-trimethoxycinnamate thymol ester, a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate are disclosed.

The invention also refers to a method of inducing, stimulating and / or promoting healing of a wound or a damaged skin area, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Equally, the invention relates to a method of preventing formation and / or recurrence of a wound or a damaged skin area in a subject being at risk of developing a wound or a damaged skin area, wherein the method comprises topically treating the skin of the subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Further, the invention relates to a method of treating rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, or skin damage caused by fragile skin, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area to be treated with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention is also directed to conditioned medium, uses thereof, compositions comprising the same, methods of producing the same as well as uses of these compositions.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

The utility model provides a device for after tumor radiotherapy chest shielding and protection. The main frame whole of device is U shape structure, and the four arounds of main frame are fixed with edge board, soft pad, and the inside of main frame is fixed with top support, bottom support, edge support respectively, and left, right chest guard seat is fixed with top support, bottom support, edge support respectively with connecting rod, and chest guard is connected with left, right chest guard seat respectively, and rectangular frame is connected with main frame, and the edge board on both sides of main frame is fixed with braces, magic tape, and connecting band is fixed on neck fixed band, and main frame is connected with neck fixed band through hanging ear, hook and connecting band. The device is combined with the chest guard of main frame and rectangular frame, which forms a gap of 3-5cm between the device and the skin, protects the external preparation applied on the skin, prevents radioactive dermatitis infection and protects the privacy of the patient, has a reasonable structure design, is simple and practical to operate, and can be widely applied in clinical treatment.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

This invention belongs to the field of medical materials technology and discloses a medical composite dressing for relieving dermatitis and eczema and its preparation method. First, mussel adhesive protein is dissolved in purified water, and the pH is adjusted to obtain a mussel adhesive protein solution. Trehalose, ectoine, and a portion of glycerin are mixed and dissolved to obtain an active ingredient composite solution. Then, the mussel adhesive protein solution and the active ingredient composite solution are mixed, and the pH is adjusted to obtain phase A. Sodium carboxymethyl cellulose is dissolved in a buffer solution in batches to obtain sodium carboxymethyl cellulose solution A and sodium carboxymethyl cellulose solution B. The two solutions are mixed, and the remaining glycerin and methylparaben are added. After adjusting the pH, phase B is obtained. Finally, phase A is added dropwise to phase B, stirred, and allowed to stand for maturation to obtain the final product. The medical composite dressing provided by this invention has a unique temperature-pH response mechanism, enabling the release of active ingredients such as ectoine and trehalose under weakly acidic conditions, achieving targeted repair and moisturizing of the inflamed area.

The present application relates to a kind of biological active microneedle patch for repairing radiation dermatitis and its preparation method and application, belong to biomedical material technical field.The microneedle patch of the present application includes backing layer and needle tip layer, wherein the material of backing layer is methacrylated hyaluronic acid with photo-crosslinking characteristics, the material of needle tip layer is silk fibroin and hyaluronic acid, and loaded with chlorogenic acid and adipose stem cell exosome as core bioactive component.The microneedle patch of the present application has excellent mechanical properties and biological activity, can minimally invasive penetration skin keratin layer barrier, realize the accurate delivery and sustained release of active ingredient to damaged tissue deep layer.Microneedle patch improves the problem of insufficient mechanical strength of natural polymer microneedle through the composite structure of "methacrylated hyaluronic acid backing + silk fibroin needle tip", realizes the synergistic effect of antioxidant, anti-inflammatory and extracellular matrix homeostasis reconstruction through "chlorogenic acid + adipose stem cell exosome", and can be used for repairing radiation dermatitis.

This utility model relates to the field of therapeutic applicators, and discloses a dermatitis treatment applicator with a rotating nozzle, comprising a can body. A connecting seat is detachably mounted on the upper outer wall of the can body. A pressing head is provided on the upper outer wall of the connecting seat. A nozzle body is provided on the left inner wall of the pressing head. A limiting groove is formed on the right inner wall of the pressing head. A movable seat is rotatably connected to the upper inner wall of the connecting seat. A limiting block is slidably connected to the upper inner wall of the movable seat. A limiting component is provided on the right inner wall of the limiting block, which is used to limit the limiting block. A protective component is provided on the front inner wall of the connecting seat. In this utility model, by setting the limiting block and locking block, the height of the limiting block can be adjusted to control the amount of medicine sprayed, preventing excessive medicine spraying due to excessive pressing force of the pressing head, thus controlling the amount of medicine sprayed and saving medicine.

A kind of nitrogen-containing heterocyclic protein inhibitor compound, its stereoisomer, tautomer or pharmaceutically acceptable salt, also provides preparation of nitrogen-containing heterocyclic compound and its use, the drug prepared using the compound is widely used in the treatment of diseases, wherein the diseases include multiple types of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, Sjogren's syndrome and scleroderma.

This application discloses the use of neuroprotective agent D1 (NPD1) in the preparation of drugs to relieve / treat chronic pruritus, relating to the field of biomedical technology. This invention provides NPD1 that can reverse spinal cord demyelination and relieve chronic pruritus. NPD1 can be used to relieve and / or treat chronic dermatitis pruritus, particularly showing excellent inhibitory effects against allergic contact dermatitis. The NPD1 can be developed into conventional lipid nanoparticles (LNPs) or other similar lipid nanoparticle drug formulations for drug delivery, possessing significant potential application value for relieving itching. The NPD1 developed in this invention can directly relieve pruritus abnormalities caused by dorsal horn demyelination of the mouse spinal cord, fundamentally inhibiting the occurrence of pruritus abnormalities in chronic dermatitis, solving the clinical problem of chronic pruritus that plagues patients with chronic dermatitis, and providing a new and effective solution for the clinical treatment of chronic dermatitis, especially pruritus in allergic contact dermatitis.

The application belongs to the technical field of medicine, and discloses skin health antipruritic liquid, which comprises raw material components: angelica, cortex moutan, white alum, forsythia, schizonepeta, baizhi, humulus, zanthoxylum, lotus house, artemisia leaf, duckweed, alkanna, aloe, honeycomb, polygonatum, stemona, sophora, fly Yang grass, cortex periplocae, melaleuca, ophiorrhiza, white milkweed, gallic, spilanthes, kochia, taraxacum, clematis, xuchangqing, biota, radix falcaliae, radix pterostupiae, red plate, snake skin, wind-preventing plant, hollyhock, oak flower, oak, radix scrophulariae, radix paeoniae, radix bupleuri, radix scrophulariae, radix paeoniae, radix scrophulariae, radix paeoniae, radix scrophulariae, borage, borax, the application has multiple effects of clearing heat and cooling blood, sterilizing and resisting inflammation, removing dampness and relieving itching, removing toxicity and resolving mass, etc., can improve or treat various skin problems such as eczema, herpes, allergic dermatitis, tinea pedis, hemorrhoids, acne, psoriasis and skin itching, and is suitable for a wide range of scenes; the process combination of crushing, screening, specific proportion mixing, fermentation, multiple filtration and accurate concentration ensures that the active ingredients in the raw materials are fully extracted and purified, avoids the loss of effective components, improves the curative effect intensity of unit volume of liquid medicine, and has quick effect after spraying, which is beneficial to actual application and operation.